Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage
Researchers Review Treatment Patterns in Secondary Progressive Multiple Sclerosis
10/20/2021
Erin McGuinness
Patients with secondary progressive multiple sclerosis (SPMS) are less likely to be treated with disease modifying therapies (DMTs) when compared to patients with relapsing remitting multiple sclerosis (RRMS), according to a review of...
Patients with secondary progressive multiple sclerosis (SPMS) are less likely to be treated with disease modifying therapies (DMTs) when compared to patients with relapsing remitting multiple sclerosis (RRMS), according to a review of...
Patients with secondary...
10/20/2021
Neurology
News
Researchers Suggest Unifying Diagnostic Criteria for Multiple Sclerosis
10/15/2021
Erin McGuinness
A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
A single, unified set of...
10/15/2021
Neurology
Patricia K. Coyle, MD: The Latest on MOG-Mediated Disease in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: The Latest on MOG-Mediated Disease in Multiple Sclerosis
02/08/2021
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting. A full transcript is provided.
In this podcast, Dr Coyle discusses the "final word" on myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting. A full transcript is provided.
In this podcast, Dr Coyle...
02/08/2021
Neurology
Patricia K. Coyle, MD: Emerging Data on Remyelination in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: Emerging Data on Remyelination in Multiple Sclerosis
12/22/2020
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle discusses the "final word" on strategies to promote remyelination in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle...
12/22/2020
Neurology
Patricia K. Coyle, MD: Updates on Neuromyelitis Optica Spectrum Disorder in Multiple Sclerosis
Podcasts
Patricia K. Coyle, MD: Updates on Neuromyelitis Optica Spectrum Disorder in Multiple Sclerosis
11/24/2020
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle discusses the "final word" on neuromyelitis optica spectrum disorder in multiple sclerosis from the ECTRIMS/ACTRIMS MSVirtual2020 meeting.
In this podcast, Dr Coyle...
11/24/2020
Neurology
Gray Matter Pathology in MS: Key Research Advances
Q&As
Gray Matter Pathology in MS: Key Research Advances
11/11/2020
At the ANA’s 145th Annual Meeting, Caterina Mainero, MD, PhD, discussed gray matter pathology in multiple sclerosis. After Dr Mainero’s presentation, Neurology Learning Network caught up with her about important research advances in this area.
At the ANA’s 145th Annual Meeting, Caterina Mainero, MD, PhD, discussed gray matter pathology in multiple sclerosis. After Dr Mainero’s presentation, Neurology Learning Network caught up with her about important research advances in this area.
At the ANA’s 145th Annual...
11/11/2020
Neurology
Burcu Zeydan, MD: Important Considerations for Aging Patients With MS
Podcasts
Burcu Zeydan, MD: Important Considerations for Aging Patients With MS
10/29/2020
In this podcast, Dr Zeydan discusses how multiple sclerosis (MS) phenotypes impact the association between aging and MS, key considerations for this patient population, and more. She recently discussed this topic at the ECTRIMS/ACTRIMS...
In this podcast, Dr Zeydan discusses how multiple sclerosis (MS) phenotypes impact the association between aging and MS, key considerations for this patient population, and more. She recently discussed this topic at the ECTRIMS/ACTRIMS...
In this podcast, Dr Zeydan...
10/29/2020
Neurology
Martin Weber, MD, Discusses MOG-Mediated Disease in Multiple Sclerosis
Podcasts
Martin Weber, MD, Discusses MOG-Mediated Disease in Multiple Sclerosis
10/15/2020
In this podcast, Dr Weber discusses clinical presentations of myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis, as well as important research developments in this field. Dr Weber recently gave a talk about...
In this podcast, Dr Weber discusses clinical presentations of myelin oligodendrocyte glycoprotein-mediated disease in multiple sclerosis, as well as important research developments in this field. Dr Weber recently gave a talk about...
In this podcast, Dr Weber...
10/15/2020
Neurology
News
Early Intensive Treatment vs Escalation: Which is More Effective for RRMS?
09/14/2020
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently...
09/14/2020
Neurology
News
Rituximab for MS: New Safety, Efficacy Data Presented at MSVirtual2020
09/11/2020
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20...
09/11/2020
Neurology
4 Questions About Prodromal Multiple Sclerosis
Q&As
4 Questions About Prodromal Multiple Sclerosis
09/07/2020
Neurology Consultant spoke with Helen Tremlett, PhD, from the University of British Columbia, whose recent study adds to increasing evidence of a multiple sclerosis prodrome. Dr Tremlett discussed this topic during the Paty Lecture at the...
Neurology Consultant spoke with Helen Tremlett, PhD, from the University of British Columbia, whose recent study adds to increasing evidence of a multiple sclerosis prodrome. Dr Tremlett discussed this topic during the Paty Lecture at the...
Neurology Consultant spoke with...
09/07/2020
Neurology

Advertisement

Migraine CME Series

Advertisement

News

Conference Coverage
Researchers Review Treatment Patterns in Secondary Progressive Multiple Sclerosis
10/20/2021
Erin McGuinness
Patients with secondary progressive multiple sclerosis (SPMS) are less likely to be treated with disease modifying therapies (DMTs) when compared to patients with relapsing remitting multiple sclerosis (RRMS), according to a review of...
Patients with secondary progressive multiple sclerosis (SPMS) are less likely to be treated with disease modifying therapies (DMTs) when compared to patients with relapsing remitting multiple sclerosis (RRMS), according to a review of...
Patients with secondary...
10/20/2021
Neurology
News
Researchers Suggest Unifying Diagnostic Criteria for Multiple Sclerosis
10/15/2021
Erin McGuinness
A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
A single, unified set of magnetic resonance imaging (MRI) criteria that can apply to relapsing remitting multiple sclerosis (MS) and primary progressive MS should be considered for future revisions to the McDonald diagnostic criteria,...
A single, unified set of...
10/15/2021
Neurology
News
Early Intensive Treatment vs Escalation: Which is More Effective for RRMS?
09/14/2020
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently exists for when and how aggressively to treat relapsing-remitting multiple sclerosis (RRMS), researchers compared the effects of early intensive treatment vs moderate-efficacy treatment followed by escalation...
Because no consensus currently...
09/14/2020
Neurology
News
Rituximab for MS: New Safety, Efficacy Data Presented at MSVirtual2020
09/11/2020
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20 monoclonal antibody, is commonly used as an off-label treatment for multiple sclerosis (MS). In a new study presented at MSVirtual2020, researchers compared the safety and efficacy of RTX at low and high doses...
Rituximab (RTX), an anti-CD20...
09/11/2020
Neurology

Advertisement

Advertisement

Alzheimer's Disease CME Series

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement